|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
73,583,000 |
Market
Cap: |
N/A |
Last
Volume: |
1,917,000 |
Avg
Vol: |
893,411 |
52
Week Range: |
$259.55 - $259.55 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Loury David J |
Executive VP, Toxicology |
|
2013-10-31 |
4 |
A |
$10.56 |
$12,024 |
D/D |
1,139 |
1,628 |
|
- |
|
Beaupre Darrin |
VP, Clin. Med. & Early Dev. |
|
2013-10-31 |
4 |
A |
$52.24 |
$8,202 |
D/D |
157 |
386 |
|
- |
|
Tan Heow |
Chief Quality&Tech Operations |
|
2013-10-31 |
4 |
A |
$52.24 |
$8,829 |
D/D |
169 |
169 |
|
- |
|
Lee Dana |
VP, Clinical Drug Safety |
|
2013-10-31 |
4 |
A |
$64.81 |
$14,972 |
D/D |
231 |
231 |
|
- |
|
Soni Manmeet Singh |
Executive VP, Finance |
|
2013-10-31 |
4 |
A |
$52.24 |
$8,411 |
D/D |
161 |
406 |
|
- |
|
Graef Thorsten |
VP, Clinical Science |
|
2013-10-31 |
4 |
A |
$52.24 |
$7,470 |
D/D |
143 |
806 |
|
- |
|
Chang Betty Y |
VP, Research/Biology |
|
2013-10-31 |
4 |
A |
$10.56 |
$1,098 |
D/D |
104 |
3,754 |
|
- |
|
Sjovall Boultbee Paula S |
EVP, Sales and Marketing |
|
2013-10-31 |
4 |
A |
$23.07 |
$1,869 |
D/D |
81 |
1,739 |
|
- |
|
Faust Elizabeth |
VP Medical Affairs |
|
2013-10-31 |
4 |
A |
$64.81 |
$21,194 |
D/D |
327 |
327 |
|
- |
|
Suchet Christopher |
VP Information Technology |
|
2013-10-31 |
4 |
A |
$64.81 |
$21,194 |
D/D |
327 |
327 |
|
- |
|
Graef Thorsten |
VP, Clinical ScienceOfficer |
|
2013-07-09 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
663 |
|
- |
|
Beaupre Darrin |
VP, Clin. Med. & Early Dev.Off |
|
2013-07-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
229 |
|
- |
|
Chang Betty Y |
VP, Research/BiologyOfficer |
|
2013-07-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,650 |
|
- |
|
Graef Thorsten |
VP, Clinical ScienceOfficer |
|
2013-07-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
263 |
|
- |
|
Shearer Scott T |
VP, Global Quality |
|
2013-06-06 |
4 |
S |
$85.17 |
$1,596,994 |
D/D |
(18,750) |
0 |
|
- |
|
Shearer Scott T |
VP, Global Quality |
|
2013-06-06 |
4 |
OE |
$30.46 |
$571,125 |
D/D |
18,750 |
18,750 |
|
- |
|
Hemmi Gregory |
VP Chemical Operations |
|
2013-05-31 |
4 |
S |
$91.96 |
$4,598,115 |
D/D |
(50,000) |
24,236 |
|
- |
|
Hemmi Gregory |
VP Chemical Operations |
|
2013-05-31 |
4 |
OE |
$0.86 |
$135,179 |
D/D |
50,000 |
74,236 |
|
- |
|
Tan Heow |
Chief of Technical Operations |
|
2013-05-31 |
4 |
S |
$91.84 |
$480,961 |
D/D |
(5,237) |
0 |
|
- |
|
Tan Heow |
Chief of Technical Operations |
|
2013-05-31 |
4 |
OE |
$27.05 |
$135,250 |
D/D |
5,000 |
5,237 |
|
- |
|
Mcgreivy Jesse |
VP, Clinical Science |
|
2013-05-31 |
4 |
S |
$91.13 |
$1,319,510 |
D/D |
(14,479) |
0 |
|
- |
|
Mcgreivy Jesse |
VP, Clinical Science |
|
2013-05-31 |
4 |
OE |
$25.33 |
$548,103 |
D/D |
14,479 |
14,479 |
|
- |
|
Love Richard B |
VP and General Counsel |
|
2013-05-31 |
4 |
S |
$89.00 |
$712,000 |
D/D |
(8,000) |
0 |
|
- |
|
Love Richard B |
VP and General Counsel |
|
2013-05-31 |
4 |
OE |
$32.38 |
$259,040 |
D/D |
8,000 |
8,000 |
|
- |
|
Sjovall Boultbee Paula S |
EVP, Sales and Marketing |
|
2013-04-30 |
4 |
A |
$52.24 |
$21,210 |
I/I |
406 |
406 |
|
- |
|
382 Records found
|
|
Page 5 of 16 |
|
|